There are no universally agreed upon firm guidelines for medical treatment for those patients with pancreatic cancer (adenocarcinoma of the pancreas) who are not candidates for surgery or who have a recurrence of the cancer after surgical resection. In part, this is because there is no one great treatment option – there are a number of medical treatment approaches for cancer of the pancreas which may be more or less appropriate, given certain variables. Also, medical treatment offerings in pancreatic cancer are often highly tailored to patient circumstance and wishes, which can be exceptionally individual.
Although, the introduction of the more widespread use of the four-drug FOLFIRINOX regimen for advanced pancreatic cancer and the later discovery of the efficacy of the Abraxane plus gemcitabine chemotherapy option have given oncologists hope for modestly improved outcomes in the treatment and care of pancreatic cancer.
In the discussion to follow…More recently, treatment for pancreatic cancer with four and five drug regimens that include 5-FU have shown themselves to offer comparable and perhaps even slightly superior results in comparison to gemcitabine alone, although side-effects may be limiting. And, we have earlier mentioned (above) the increased survival advantages for many with pancreatic cancer of the FOLFIRINOX as well as the Abraxane plus gemcitabine regimens.
Generally, in locally advanced unresectable pancreatic cancer, chemotherapy plus radiation is often prescribed as standard medical treatment. As early as 1981, a landmark report by the Gastrointestinal Tumor Study Group demonstrated significant survival advantage to those patients with locally unresectable adenocarcinoma of the pancreas who received both chemotherapy (5-FU) and radiation. This combination chemoradiation gave better medical outcomes for pancreatic cancer than either chemotherapy or radiation treatment alone.
There have been a wide range of studies involving the delivery mode, method and amount of radiation to the pancreatic cancer tumor area. These have included such approaches as external beam radiotherapy, intraoperative radiotherapy and the seeding of the actual tumor area with radioactive pellets or with radioactive colloidal solution (brachytherapy). 5-FU (sometimes with in combination with drugs which enhance its effect) has been perhaps the standard chemotherapy agent in many chemoradiation regimens, but the drug-agents mitomycin-C and cisplatin (a platinum-containing compound) are among the stable of chemotherapy agents which have also been utilized. Also, a number of studies have begun looking at the drug agent gemcitabine as an effective radiosensitizer for combination with radiation therapy in chemoradiation type medical treatment for locally advanced unresectable pancreatic cancer.
According to some studies, chemoradiation medical treatment may push back the cancer enough to allow some patients (a minority) with apparent locally unresectable pancreatic cancer who otherwise might not be candidates – to then be eligible for surgical resection.
The median survival duration from diagnosis with chemotherapy medical treatment in unresectable locally advanced cancer of the pancreas has been reported as 6-12 months.
As the pancreatic cancer becomes widespread, although there may be creative modalities by way of exception, the advantages of radiation (more of a field range) are increasingly diminished. Thus, standard medical treatment for advanced cancer of the pancreas typically involves chemotherapy type agents alone.
The chemotherapy agent 5-FU (fluorouracil) which has been in use as medical treatment against pancreatic cancer for more than 40 years, acts in several ways, but principally as a thymidylate synthase inhibitor, interrupting the action of an enzyme which is a critical factor in the synthesis of pyrimidine – a building block which is important in DNA replication. The underlying principle in many standard treatment agents has to do with interfering with the normal progression of the cell cycle. As cancer is caused by uncontrolled cell growth, one if its central weaknesses due to this rapid almost chaotic growth is inherent genetic instability. If a medical treatment agent hurts the ability of the cell to progress through its normal replication cycle, although this will tend to hurt ALL of the cells in the body, its effect will be selectively severe on unstable and rapidly growing cells – the cancer itself.
Gemcitabine is an approved medical treatment agent which tends to offer increased median survival duration (and increased one year survival rates) for pancreatic cancer as compared to 5-FU alone. It also appears in individual cases to confer improved quality-of-life measures over medical treatment with 5-FU and even over no medical treatment at all. Additionally, the targeted therapy Tarceva has been approved in the U.S. for the medical treatment of pancreatic cancer. More recently, treatment for pancreatic cancer with four and five drug regimens that include 5-FU have shown themselves to offer comparable and perhaps even slightly superior results in comparison to gemcitabine alone, although side-effects may be limiting. Please note our FOLFIRINOX grug regimen information, and search for other entries in the Pancreatica Blog.
The following are descriptions of titles of abstracts of medical journal articles that may be interesting or useful to those who are interested in further information about this topic. These abstracts can be searched Here.
Our science board is composed of:
James Abbruzzese, MD Chief, Medical Oncology Duke University
Markus Büchler, MD Chairman, Surgery Heidelberg University, Germany
Ralph Hruban, MD Director, GI / Liver Pathology Johns Hopkins University
Eileen O’Reilly, MD Associate Director for Clinical Research – Memorial Sloan-Kettering Cancer Center
Margaret Tempero, MD Chief, Medical Oncology University of California at San Francisco
Our Philosophy About Pancreatic Cancer
Pancreatic cancer is a serious disease. Taking an aggressive rational stance at the earliest possible time, supported by the best medical team, and treated in the most appropriate manner gives the best chance for survival.
We believe in strong patient-physician bonds, scientifically-based treatment, and that comfort can come from knowing that everything that reasonably can be done – is being done.
That the best approach is meeting cancer of the pancreas head-on and armed with the best available information.
To Safely make a Donation via Text, Text the Code FIGHTPC to number 44-321
Making IMPACT for Pancreatic Cancer Together!
MONTHLY MEMORIAL GIFTS: YOUR TRIBUTE TO A LOVED ONE
Regular giving can be an opportunity to pay tribute in honour of a loved one. Your monthly gift will go directly to promoting awareness, increasing education, furthering pancreatic cancer research aimed at early diagnosis and, helping patients and families impacted by the effects of pancreatic cancer.
Simply select “Monthly” after choosing the amount you would like to give.
PROPOSED: Every newly diagnosed person with pancreatic cancer (ductal adenocarcinoma of the pancreas) should receive genetic screening prior to beginning treatment – to test for germline genetic mutations in the homologous recombination DNA repair pathway, including genes such as BRCA1, BRCA2, PALB2, and others. These results, in from 12% to 17% of pancreatic cancer patients, suggest that treatment that includes DNA cross-linking agents such as platinum compounds or PARP inhibitors may be superior to standard best practices therapy.
OFFER: Color Genomics offers a 30-gene cancer panel for $224 (normally $249) when the Promotion Code “PANCREATIC” is entered at checkout (price will reduce upon entering this code). This is a physician-ordered saliva kit. Click Here for more information
RATIONALE: The age of precision medicine in pancreatic cancer is approaching … [MORE]
This year an estimated 57,600 Americans will be diagnosed with pancreatic cancer. Approximately 47,050 Americans are expected to die from the disease. There are many reasons why the outcome for pancreatic cancer patients is bleaker than for most other cancer types. There are no reliable methods to detect the disease early, and there are very few effective treatment options. Which is why we are so focused on supporting research for early diagnosis.
Together with You our Mission is to promote awareness, increase education, and further pancreatic cancer research aimed at early diagnosis.
Most of our fundraisers, supporters, and volunteers, have been in one way or another, personally effected by this disease. We want to acknowledge what hardships you may have gone through (or are currently facing) and sincerely thank you for visiting our site!
Choose a walk, run, or any other activity that you like and work to raise donations leading up to your Event! Simply set up your participation page and we will be in touch!
Already registered for your next Race? Dedicate your participation to Pancreatic Cancer. Simply set up your participation page and together we will work towards our shared mission!
Creating a Facebook Fundraiser is easy: Click the Link below and Facebook will take you through the steps! Dedicate your Birthday or another important date to honor a loved one.
CREATE YOUR OWN FUNDRAISER
Create your own fun, choose something you already love to support pancreatic cancer! Simply set up your participation page, include the details of your fundraiser on your page, and get the word out!
Cancer Patients Alliance is a 501(c)(3) non-profit. Initiatives include, ToFightCancer.com and Pancreatica.org. All Donations are tax-deductible.
Pancreatic cancer is expected to become the 2nd leading cause of cancer-related death by the year 2020. There are many reasons why the outcome for pancreatic cancer patients is much bleaker than for most other cancer types. There are no reliable methods to detect the disease early, and there are very few effective treatment options.
|There remains a dire need for more research and an increase in focused funding for pancreatic cancer. Your Donation will go directly to promoting awareness, increasing education, and furthering pancreatic cancer research aimed at early diagnosis.|
Best of the Blog
Pancreatic cancer has one of the worst survival rates among cancers. Patients can expect as low as a 9% chance to live for at least five years
Hermes Soto, who turned 5 on Monday, will not be celebrating his birthday with friends. Instead, he is bracing for his 15th chemotherapy session to
Call 1-800-433-0464 for a free service that will place you in contact with a fellow survivor, or to volunteer to contact someone more recently diagnosed.
One of the observations that physicians often made when the standard of care treatment typically consisted of the chemotherapy drug agent of gemcitabine alone, was that many patients with pancreatic cancer (ductal adenocarcinoma of the pancreas) seemed to feel better after the initiation of treatment… More Here
Join us on Social Media !